• Home
  • >
  • Suven Pharmaceuticals Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/suven-pharmaceuticals-ltd.png Logo

Suven Pharmaceuticals Ltd Financial Statement

Suven Pharmaceuticals Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue226.79238.82354.08
Operating Expense144.69127.27174.14
Net Profit52.3674.73124.29
Net Profit Margin23.0931.2935.1
Earning Per Share2.062.944.88
EBIDTA78.03110177.9
Effective Tax Rate15.9221.7722.96

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Suven Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual1,340.331,320.221,009.72
Operating Expenses Annual773.79740.8569.24
Operating Profit Annual612.9712.92508.45
Interest Annual5.446.239.14
Depreciation47.3338.7131.25
Net Profit Annual411.29453.8362.34
Tax Annual148.44213.78105.33

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Suven Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning44.567.1811.7
Cash Flow from Operations450.91330382.55
Cash Flow from Investing-194.84-136.14-311.4
Cash Flow from Financing-235.83-156.48-75.66
Cash Flow at the End64.844.567.18

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Suven Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)46.2848.5550.61
PBIT Margin (%)42.7245.5947.47
PBT Margin (%)39.3640.2543.4
Net PROFIT Margin (%)32.5242.2730.57
Return On Networth / Equity (%)25.2129.7935.78
Return On Networth /Employed(%)33.2240.6240.45
Return On Assets (%)25.3737.6225.98
Total Debt / Equity(X)0.050.090.18
Asset Turnover Ratio (%)0.780.890.85

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Suven Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual663.33534.19441.34
Total Current Assets Annual1,011.051,127.93564.79
Non Current Assets Annual954.7701.66909.69
Total Shareholders Funds Annual1,735.181,527.181,180.8
Total Assets Annual1,965.741,829.591,474.48

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Suven Pharmaceuticals Ltd Earning Calls
Dec 2023
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Suven Pharmaceuticals Ltd has a market capitalization of 12,033.29 Cr. Value Research classifies it as a Large-Cap company.

Yes, Suven Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.04.

In FY 2023, Suven Pharmaceuticals Ltd recorded a total revenue of approximately 1,340.33 Cr marking a significant milestone in the company's financial performance.

Suven Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.0% and 0.1% annually, respectively..

Suven Pharmaceuticals Ltd's current PE ratio is 29.26.

Suven Pharmaceuticals Ltd's ROCE averaged 36.3% from the FY ending March 2021 to 2023, with a median of 36.0%. It peaked at 41.5% in March 2022, reflecting strong capital efficiency over the period..

Suven Pharmaceuticals Ltd's latest EBIT is Rs. 565.17 Cr, surpassing the average EBIT of Rs. 571.93 Cr over the 5 years..